AI Article Synopsis

  • - The study investigates the impact of EGFR and KRAS mutations on lung adenocarcinoma progression in patients who underwent tumor resection, analyzing data from 241 cases at Stanford University Hospital between 2008 and 2022.
  • - Results show that patients with KRAS mutations exhibited poorer clinical outcomes, including larger tumor sizes and worse survival rates compared to those with EGFR mutations, particularly in cases with multifocal pulmonary nodules.
  • - The findings suggest that KRAS mutations are associated with more aggressive tumor characteristics and worse prognosis, highlighting the need for further exploration of these mutations in lung adenocarcinoma.

Article Abstract

Background: Epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma (KRAS) are the two most common oncogenic drivers in lung adenocarcinoma, and their roles still need further exploration. Here we aimed to compare the clinical impact of and mutations on disease progression in resected unifocal and multifocal lung adenocarcinoma.

Methods: Clinicopathologic and genomic data were collected for patients who underwent resection of lung adenocarcinoma from 2008 to 2022 at Stanford University Hospital. Retrospective review was performed in 241 patients whose tumors harbored (n=150, 62.2%) or (n=91, 37.8%) mutations. Clinical outcome was analyzed with special attention to the natural history of secondary nodules in multifocal cases wherein the dominant tumor had been resected.

Results: We confirm that compared with mutations, patients with mutations had more smokers, larger tumor size, higher TNM stage, higher positron emission tomography (PET)/computed tomography (CT) standard uptake value max, higher tumor mutation burden, and worse disease-free survival and overall survival on univariate analysis. For patients with multifocal pulmonary nodules, the median follow-up of unresected secondary nodules was 55 months. Secondary nodule progression-free survival (SNPFS) was significantly worse for patients with mutations than those with mutations (mean 40.3±6.6 67.7±6.5 months, P=0.004). Univariate analysis showed tumor size, tumor morphology, pathologic TNM stage, and mutations were significantly associated with SNPFS, while multivariate analysis showed only mutations were independently associated with worse SNPFS (hazard ratio 1.752, 95% confidence interval: 1.017-3.018, P=0.043).

Conclusions: Resected lung adenocarcinomas with mutations have more aggressive clinicopathological features and confer worse prognosis than those with mutations. Secondary pulmonary nodules in multifocal cases with dominant -mutant tumors have more rapid progression of the secondary nodules.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11225054PMC
http://dx.doi.org/10.21037/tlcr-24-165DOI Listing

Publication Analysis

Top Keywords

lung adenocarcinoma
12
secondary nodules
12
mutations
11
clinical impact
8
impact mutations
8
unifocal multifocal
8
multifocal lung
8
nodules multifocal
8
multifocal cases
8
cases dominant
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!